Single Subject Neratinib in Bladder Cancer (NRR)

• Status: No longer available
• Trial end date: 2014-06-01
• Target enrollment: 0
• Participant gender: Male

Summary

This study will be a single subject study to evaluate the efficacy of the HER2 kinase inhibitor, neratinib, in a patient with metastatic bladder cancer harboring a HER2-GRB7 gene fusion.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Criteria

Inclusion Criteria:

• none

Exclusion Criteria:

• none

We have received FDA approval for a single subject Investigational New Drug (IND) Application to treat a specific patient with the HER2 kinase inhibitor neratinib. Therefore there is no inclusion / exclusion criteria.